Latest Andrew Witty Stories
LONDON, February 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline today said it had posted a strong performance in a challenging year with a return to sales growth for the first time since 2007. In an interview on http://www.cantos.com CEO Andrew Witty also announced a reduction in the investment into treatments for pain and depression and a restructuring of R&D. He said: "Now obviously I don't like to see anybody leave the organisation or there to be any job losses.
PHILADELPHIA, Feb. 1 /PRNewswire-FirstCall/ -- On Thursday, February 4, 2010, GlaxoSmithKline plc will announce its full year financial results for the year ended December 31, 2009.
A UK newspaper report showed that a British drug maker GlaxoSmithKline (GSK) is set to make thousands of chemical compounds that have the potential to cure malaria available for research.
PHILADELPHIA and LONDON, Jan.
PHILADELPHIA, July 16 /PRNewswire-FirstCall/ -- On Wednesday, July 22nd, GlaxoSmithKline plc (NYSE: GSK) will announce its second quarter financial results for the three months ended June 30, 2009.
PHILADELPHIA, April 21 /PRNewswire-FirstCall/ -- On Wednesday, April 22, 2009 GlaxoSmithKline plc (NYSE: GSK) will announce its first quarter financial results for the three months ended March 31, 2009.
British pharmaceutical giant GlaxoSmithKline said Monday it agreed to purchase skin-products producer Stiefel Laboratories for $2.9 billion. The deal includes the assumption of $400 million of Stiefel's debt, but will add a robust development pipeline to GlaxoSmithKline's product line, the company said in a statement.
Stiefel, the world's largest independent dermatology company, acquired by GSK in deal valued at up to $3.6 billion New global business will have combined revenues of approximately $1.5 billion and robust new product pipeline Significant step forward to grow and diversify GSK's business, providing immediate new revenue and synergy opportunities LONDON, April 20 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) and Stiefel Laboratories Inc.
LONDON, April 16 /PRNewswire-FirstCall/ -- Pharmaceutical companies GlaxoSmithKline and Pfizer today announced an "innovative agreement" to pool their HIV assets creating a new world-leading, specialist HIV company. The deal will see the drug giants combine their existing HIV product and their pipelines with GSK holding 85% of the company and Pfizer 15%. The deal will be marginally dilutive to GSK earnings in the first two years but in a video interview Group CEO Andrew Witty said...
- The parings of haberdine; also, any kind of fragments.